RESULTS	Gastrointestinal symptoms ( which led to more discontinuations in the group receiving 150 mg twice a day than in the placebo group ) and increases in levels of liver aminotransferases were more frequent in the group receiving 150 mg of BIBF 1120 twice daily than in the placebo group .\